018 / ADDITIONAL DISCLOSURES ON SHARE-BASED PAYMENTS INSTRUMENTS

 

 

Group Share Plan/Performance Share Plan3

 

 

Outstanding performance share units at the start of the financial year

Performance share units granted in the financial year

 

Performance share units expired in the financial year

Performance share units exercised in the financial year

Outstanding performance share units at the end of the financial year

Total cost for share-based payment4

 

 

Number

Number

Fair value of the grant in EUR

Number

Number

Number

in EUR

1

Executive Board members Sabine Eckhardt, Dr. Gunnar Wiedenfels and Dr. Ralf Schremper also have PSUs from work performed before they joined the Executive Board. These were not granted as remuneration for their role on the Executive Board and are thus not included in the overview. Dr. Gunnar Wiedenfels left the Executive Board effective March 31, 2017 and Dr. Ralf Schremper effective July 31, 2017. Information on share-based payment instruments in their case can be found in the chapter regarding total compensation of former members of the Executive Board.

2

Thomas Ebeling left the Executive Board as of February 22, 2018, and Christof Wahl as of July 31, 2018. For information on the effects on the Group Share Plan, please refer to “Notes on the Compensation of Departed or Departing Executive Board Members”.

3

Nominal amounts of PSUs when granted. PSUs from the Group Share Plan were granted for the last time in financial year 2017; in financial year 2018, they were granted under the new Performance Share Plan.

4

The total cost in the financial year 2018 includes an adjustment of the conversion factor for the performance share units granted (86%) for the Group Share Plan 2015 and was measured as of December 31, 2018. No adjustments were made due to anti-dilution protection or an individual increase by the Supervisory Board. The total cost in the financial year 2017 includes an adjustment of the conversion factor for the performance share units granted (100%) for the Group Share Plan 2014 and was measured as of December 31, 2017. The total cost for Conrad Albert and Christof Wahl is negative due to declines in the share price in financial year 2018; the total cost for Dr. Ralf Schremper is negative due to declines in the share price in financial year 2017.

Max Conze

2018

0

34,438

857,500

0

0

34,438

45,623

2017

Conrad Albert

2018

95,639

44,177

1,100,000

0

25,658

114,158

– 86,591

2017

90,849

30,019

800,000

0

25,229

95,639

451,938

Dr. Jan Kemper

2018

30,019

39,358

980,000

0

0

69,377

63,343

2017

0

30,019

800,000

0

0

30,019

382,556

Sabine Eckhardt1

2018

30,019

32,531

810,000

0

0

62,550

49,454

2017

0

30,019

800,000

0

0

30,019

382,556

Jan David Frouman

2018

53,577

32,531

810,000

0

0

86,108

119,065

2017

23,558

30,019

800,000

0

0

53,577

468,226

Thomas Ebeling2

2018

82,024

0

0

49,952

32,072

0

86,717

2017

113,560

0

0

0

31,536

82,024

3,425

Christof Wahl2

2018

77,577

0

0

26,897

0

50,680

– 252,937

2017

47,558

30,019

800,000

0

0

77,577

555,506

Dr. Gunnar Wiedenfels1

2018

2017

39,962

0

0

25,870

14,092

0

38,303

Dr. Ralf Schremper1

2018

2017

39,962

0

0

15,879

0

24,083

– 11,643

Total

2018

368,855

183,035

4,557,500

76,849

57,730

417,311

24,673

2017

355,449

150,095

4,000,000

41,749

70,857

392,938

2,270,867